These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9266723)

  • 41. Lambert-Eaton myasthenic syndrome in childhood.
    Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen.
    Leveque C; Hoshino T; David P; Shoji-Kasai Y; Leys K; Omori A; Lang B; el Far O; Sato K; Martin-Moutot N
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3625-9. PubMed ID: 1314395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.
    Pardo NE; Hajela RK; Atchison WD
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1009-20. PubMed ID: 16982704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
    Flink MT; Atchison WD
    J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
    Flink MT; Atchison WD
    J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome.
    Martin-Moutot N; De Haro L; Seagar M
    J Neuroimmunol; 2008 Jun; 197(1):47-53. PubMed ID: 18474401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of voltage-dependent Ca2+ channels on low and high frequency mediated neurotransmission in guinea-pig ileum and rat vas deferens.
    Tran S; Boot JR
    Eur J Pharmacol; 1997 Sep; 335(1):31-6. PubMed ID: 9371543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rank-order inhibition by omega-conotoxins in human and animal autonomic nerve preparations.
    Sanger GJ; Ellis ES; Harries MH; Tilford NS; Wardle KA; Benham CD
    Eur J Pharmacol; 2000 Jan; 388(1):89-95. PubMed ID: 10657551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation.
    Nagel A; Engel AG; Lang B; Newsom-Davis J; Fukuoka T
    Ann Neurol; 1988 Oct; 24(4):552-8. PubMed ID: 2853605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells.
    Engisch KL; Rich MM; Cook N; Nowycky MC
    J Neurosci; 1999 May; 19(9):3384-95. PubMed ID: 10212298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals.
    Prior C; Lang B; Wray D; Newsom-Davis J
    Ann Neurol; 1985 Jun; 17(6):587-92. PubMed ID: 2992356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
    Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Autoimmune myasthenia and Lambert-Eaton myasthenic syndrome. Physiopathologic concepts].
    Eymard B
    Ann Med Interne (Paris); 1989; 140(6):462-6. PubMed ID: 2696402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
    Kitanosono H; Shiraishi H; Motomura M
    Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Type 2 fiber predominance in Lambert-Eaton myasthenic syndrome.
    Squier M; Chalk C; Hilton-Jones D; Mills KR; Newsom-Davis J
    Muscle Nerve; 1991 Jul; 14(7):625-32. PubMed ID: 1922168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity.
    Lang B; Vincent A; Murray NM; Newsom-Davis J
    Ann Neurol; 1989 Mar; 25(3):265-71. PubMed ID: 2543262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Binding of Lambert-Eaton myasthenic syndrome IgG to synaptosomal proteins does not correlate with an inhibition of calcium uptake.
    Martin-Moutot N; Lang B; Newsom-Davis J; Seagar M
    Neurosci Lett; 1995 Mar; 187(2):115-8. PubMed ID: 7783957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential involvement of N-type calcium channels in transmitter release from vasoconstrictor and vasodilator neurons.
    Morris JL; Ozols DI; Lewis RJ; Gibbins IL; Jobling P
    Br J Pharmacol; 2004 Mar; 141(6):961-70. PubMed ID: 14993106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
    Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
    Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.